The effects of bortezomib on EBV⁺T or NK cells from systemic CAEBV patients. (A) The PBMCs from 9 systemic CAEBV patients and 2 healthy donors were treated with bortezomib in the presence of IL-2 for 48 hours, and the viable cell number was estimated using the XTT assay and expressed in arbitrary units. The data represent the mean plus or minus SD of 3 independent experiments. (B) PBMCs from systemic CAEBV patients (CD4-3, CD8-3, and CD4/CD56-1) were treated with 5 nM bortezomib for 24 hours and 48 hours. The mRNA expression of IFN-γ and TNF-α in PBMCs was examined by qRT-PCR.